BCLI

Brainstorm Cell Therapeutics Inc

Add to Watchlist

Advanced Chart

0.000

-1.17(-100.000%)1D

Overview
Forecast
Valuation
Earnings

High

Open

VWAP

Vol

Mkt Cap

24.63M

Low

Amount

EV/EBITDA(TTM)

Total Shares

68.34M

6.22M

EV/OCF(TTM)

P/S(TTM)

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

-0.470

-7.84%

-0.330

-45%

Estimates Revision

The market is revising No Change the revenue expectations for Brainstorm Cell Therapeutics Inc. (BCLI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 7.83%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+7.83%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast BCLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCLI is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0

Low

6.00

Averages

6.00

High

6.00

Current: 0

Low

6.00

Averages

6.00

High

6.00

Maxim

Buy

Hold

downgrade

2025-07-23

Reason

Maxim

Price Target

2025-07-23

downgrade

Buy

Hold

Reason

Maxim downgraded BrainStorm to Hold from Buy.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Brainstorm Cell Therapeutics Inc (BCLI.O) is -0.83, compared to its 5-year average forward P/E of -4.26. For a more detailed relative valuation and DCF analysis to assess Brainstorm Cell Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.26

Current PE

-0.83

Overvalued PE

-1.02

Undervalued PE

-7.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.38

Current EV/EBITDA

-0.70

Overvalued EV/EBITDA

0.32

Undervalued EV/EBITDA

-1.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.26

Current PS

0.00

Overvalued PS

14.81

Undervalued PS

-6.29